MoneyWorks4Me

Cipla enters into strategic agreement with BioQ Pharma

07 Jan 2016 Evaluate

Cipla has entered into a strategic distribution, supply and development agreement with the US-based BioQ Pharma for registration and commercialisation of the latter’s Ropivacaine infusion system, used in treating post-operative pain, in India.

The Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQ Pharma’s unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.

Cipla’s proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma’s proprietary unit-dose, large volume infusion pharmaceuticals to India’s healthcare market.

Cipla Share Price

1416.00 -15.85 (-1.11%)
19-Aug-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1898.00
Dr. Reddys Labs. 1171.00
Cipla 1416.00
Lupin 2220.00
Zydus Lifesciences 1105.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: